Investors & Owners


During the short history of the company, Marinomed’s research and management team has already demonstrated its success in the research, development and marketing of its products. Marinomed has surpassed the expectations of its investors to date.


Foundation of Marinomed, Seed investment via aws, investment by Acropora


Market launch of the first Carragelose® product and equity investment by Acropo


First-time investment by ARAX Capital Partners (atypical silent partner)


Completion of a joint round of funding involving aws Mittelstandsfonds Beteiligungs GmbH & Co KG, Invest Unternehmensbeteiligungs AG, together with private investors from the management team and company environment


Change of company’s legal form to a stock corporation

Issue of a convertible bond with a conversion option in the event of an IPO


IPO in February, quotation in the prime market segment at Vienna Stock Exchange


The founders and management team own around 27% of Marinomed, while the remaining shares are held by strategic investors or holding companies. ARAX Capital Partners is also an atypical silent partner in the business via three holding companies.

Marinomed is supported by several public funding bodies, including: 

Wirtschaftsagentur Wien

Österreichische Forschungsförderungs GmbH (FFG)

INiTS Universitäres Gründerservice Wien GmbH

Austria Wirtschaftsservice GmbH (AWS)

Publication of a participation notification:
Marinomed Biotech AG
Veterinärplatz 1
1210 Vienna, Austria
Telefon: +43 1 25077 4460
Fax: +43 1 25077 4493